Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
Date:11/8/2010

reparing to initiate a Phase IIb study of ANA598, the Company's direct-acting antiviral or DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor StatementStatements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to (i) the plans, timing and trial design of the planned ANA598 Phase IIb and ANA773 Phase IIa studies; (ii) the belief that the design of the planned ANA598 Phase IIb study will support a broad range of potential treatment opportunities in future Phase III studies; (iii) assessments of the potency and safety profile of ANA598 based on the 12 week results; and (iv) references to exploring potential strategic transactions.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies, including the ANA598 data presented at AASLD and available on Anadys' website, may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval.  Also, Anadys cannot provide any assurances that activities related to its exploration of potential strategic transactions will result in a transaction of a particular structure, on favorable terms, or at all. In addition, Anadys' results may be affected by competition from other biotechnology and pharma
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Inc.,(Nasdaq: MEDX ) today announced interim ... an investigational oncology immunotherapy, as monotherapy or ... castration,resistant prostate cancer (mCRPC). Data presented showed ... was clinically active and,generally well-tolerated. Preliminary evidence ...
... and REGENSBURG, Germany, June 2 "A ... in recurrent or refractory anaplastic,astrocytoma suggests a ... commented Prof. Ulrich Bogdahn, Neuro-Oncologist and Coordinating,Investigator ... with AP,12009 in recurrent or refractory high-grade ...
Cached Medicine Technology:Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting 2Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting 3Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting 4Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 2Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 3Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 4
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
(Date:4/17/2014)... has the potential to ward off depression among retirees, ... published online in The Journals of Gerontology, ... In the article " Internet Use and Depression Among ... Analysis ," the authors report that Internet use reduced ... among their study sample. , Late-life depression affects ...
(Date:4/17/2014)... days to find a colored ribbon representing a disease. A ... what color ribbon does one think of with lung cancer?, ... many suffering from the disease, black may be the only ... of lung cancer patients, primarily smokers between the ages of ... the stigma often felt by these patients, the emotional toll ...
(Date:4/17/2014)... world is less than 40 years away from a ... and governments, according to a top scientist at the ... in human history, food production will be limited on ... and energy," said Dr. Fred Davies, senior science advisor ... could become as politically destabilizing by 2050 as energy ...
Breaking Medicine News(10 mins):Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Food shortages could be most critical world issue by mid-century 2
... over age 65, experts note, , THURSDAY, May 13 ... heartbeat known as atrial fibrillation in a certain way, ... forms of dementia, new research finds. , In atrial ... causing blood to pool and increasing the potential of ...
... who need more supplementation, study suggests , THURSDAY, May ... in the United States don,t get enough vitamin D, ... prenatal vitamins that many women take do not always ... researchers from the University of Colorado Denver School of ...
... ... research studies of the jellyfish protein apoaequorin accessible for individuals with debilitating conditions. People ... the research arm of Quincy Bioscience. , ... Madison, WI (Vocus) May 13, 2010 -- Quincy Bioscience announces the launch of ...
... ... RQi enterprise™ registration quality improvement solution allows for pre-registration information to be QA managed ... ... Technologies is proud to announce that Piedmont Healthcare Inc. has selected RQi enterprise™ ( ...
... ... Hearing Loss and Hearing Aids ( http://www.aidright.com ) , ... (PRWEB) May 13, 2010 -- AidRight audiology professionals ... caregiver. Through extensive informational portals and a trusted provider network, their newly relaunched ...
... senior citizen,s health, yet fewer than half of all seniors see ... attention are far less likely to engage in any of the ... medications or getting a cane or walker that might prevent ... Center for Health Policy Research. In the study, ...
Cached Medicine News:Health News:Treating Common Irregular Heartbeat Might Also Ward Off Alzheimer's 2Health News:Treating Common Irregular Heartbeat Might Also Ward Off Alzheimer's 3Health News:Many Pregnant Woman Not Getting Enough Vitamin D 2Health News:Quincy Bioscience Launches HOPETrials.com; Research Studies More Accessible For Participants 2Health News:Kramer Healthcare Technologies' RQi enterprise™ Revenue Cycle Solution Selected by Piedmont Healthcare 2Health News:Caregivers Find Hearing Loss Newly Relaunched Website a Welcome Help 2Health News:Falls and follow-ups: Medical attention following a fall critical to senior health 2
... MRAnywhere stands for Medical Records ... Medical Records (EMR) software that ... from within your office, hospital, ... Web. MRAnywhere offers conversion from ...
SOAPware is an Electronic Health Record for clinics. We provide tools to link to billing systems, hospitals, labs, etc....
... Medical Record Software Interface ... Interface with programs, populates ... custom reports. Accumedics Electronic ... is Microsoft compatible allowing ...
... VersaSuite EHR is designed to improve the ... offers the clinician the ability to capture ... in text, image, audio or video formats. ... provides a familiar contemporary windows interface and ...
Medicine Products: